Search results for "D86"

showing 10 items of 34 documents

TLR2 and Dectin-1 Signaling in Mouse Hematopoietic Stem and Progenitor Cells Impacts the Ability of the Antigen Presenting Cells They Produce to Acti…

2020

Microbial recognition by pattern recognition receptors (PRRs) expressed on hematopoietic stem and progenitor cells (HSPCs) not only activates myelopoiesis but also programs the function of the monocytes and macrophages they produce. For instance, changes in HSPC programming modify the ability of macrophages derived from them to produce inflammatory cytokines. While HSPCs exposed to a TLR2 agonist give rise to tolerized macrophages (lower proinflammatory cytokine production), HSPCs treated with Dectin-1 ligands produce trained macrophages (higher proinflammatory cytokine production). However, nothing is known about the impact of HSPC exposure to microbes on the function of antigen presenting…

CD4-Positive T-LymphocytesOvalbuminhematopoietic stem and progenitor cellsCD4 T cellsAntigen-Presenting CellsMice Transgenicantigen presenting cellsLymphocyte Activationinnate immune memoryProinflammatory cytokineLipopeptidesCandida albicansAnimalsTLR2Lectins C-TypeProgenitor cellAntigen-presenting celllcsh:QH301-705.5CD86CD40biologyChemistryCommunicationHistocompatibility Antigens Class IIZymosanGeneral MedicineTh1 CellsHematopoietic Stem CellsAcquired immune systemToll-Like Receptor 2Cell biologyMice Inbred C57BLlcsh:Biology (General)biology.proteinCytokinesTh17 CellsMyelopoiesisCD80Dectin-1Signal TransductionCells
researchProduct

Expresión de las moléculas del Complejo Mayor de Histocompatibilidad clase II y moléculas co-estimuladoras en carcinomas orales in vitro

2005

El descubrimiento de que el epitelio escamoso estratificado que cubre la mucosa oral podia expresar moleculas del Complejo Mayor de Histocompatibilidad clase II en varias condiciones patologicas de tipo inflamatorio abrio la posibilidad de que los queratinocitos orales sean celulas inmunologicamente activas, las cuales pueden funcionar con .celulas presentadoras de antigenos'ñ. Para una efectiva activacion de los linfocitos T, las celulas presentadoras de antigenos requieren, ademas de la expresion de moleculas del Complejo Mayor de Histocompatibilidad clase II, senales co-estimuladoras. El proposito del presente estudio fue determinar la expresion de moleculas del Complejo Mayor de Histoco…

CD80UNESCO::CIENCIAS MÉDICASCD40CD86Complejo Mayor de Histocompatibilidadepitelio oralOdontología:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludcarcinoma oral
researchProduct

CD40 signalling induces IL-10-producing, tolerogenic dendritic cells

2010

Dendritic cells (DC) are potent antigen-presenting cells capable to induce efficient antigen-specific T cell responses in vitro and in vivo. Herein, the maturation process is of great significance, as immature DC (iDC) are known to induce rather regulatory than effector T cell differentiation. This study was designed to characterize the role of the CD40-CD40L pathway for differentiation and function of human DC. Therefore, iDC were stimulated through CD40-CD40L interaction by transduction of DC with adenoviral vectors encoding for CD40L (Ad-CD40L). Resulting DC (CD40L-DC) were analysed concerning their phenotype, cytokine profile and T cell stimulatory capacity. Transduction induced a DC ph…

CD86CD40T cellReceptor expressionchemical and pharmacologic phenomenahemic and immune systemsDermatologyDendritic cellBiologyBiochemistryCell biologystomatognathic diseasesInterleukin 10medicine.anatomical_structureImmunologymedicinebiology.proteinMolecular BiologyCD80CD8Experimental Dermatology
researchProduct

B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy.

2005

The efficacy of T cell-based immunotherapy is primarily due to efficient cellular activation that requires the engagement of 2 separate signals, i.e., via the T cell receptor complex and via co-stimulatory molecules the prototype of which is CD28. In cellular activation, the CD28 ligands B7-1 (CD80) and B7-2 (CD86) are thought to play nearly identical roles in T cell activation. We monitored the T cell response upon co-culture with HLA Class I-matched and mismatched renal carcinoma cells, respectively, that express different levels of B7-1 and B7-2, respectively. In a HLA Class I-mismatched co-culture, T cell proliferation, IFN-γ and GM-CSF secretion equally depend on the levels of B7-1 and…

CD86Cancer Researchmedicine.medical_treatmentT cellT-LymphocytesCD28ImmunotherapyHuman leukocyte antigenStreptamerBiologyKidney Neoplasmsmedicine.anatomical_structureOncologyHLA AntigensCell Line TumorImmunologymedicineB7-1 AntigenCytotoxic T cellHumansB7-2 AntigenImmunotherapyLymphocyte Culture Test MixedCarcinoma Renal CellCD80International journal of cancer
researchProduct

Isolation of Differentially Expressed Genes in Epidermal Langerhans Cells

1997

Epidermal Langerhans cells (LC) represent immature dendritic cells (DC) resident in the skin, which are not yet able to prime naive T cells1. In vitro cultivation of LC in the presence of keratinocytes, supplying survival and differentiation signals, induces maturation events in LC2. These are highlighted by the downregulation of the biosynthesis of MHC class II molecules3, by the upregulation of the surface expression of adhesion and costimulatory molecules like CD80, CD86, CD54 and CD584,5, and by the acquisition of a potent immunostimulatory capacity for T cells6. Mature LC are potent inducers of naive T cells. Thus LC represent an ideal model system to investigate the maturation of DC (…

CD86Differential displaychemistry.chemical_compoundMHC class IIBiosynthesischemistryDownregulation and upregulationbiology.proteinInducerBiologyCD80In vitroCell biology
researchProduct

ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells

2002

With newly generated ICOS-ligand (ICOS-L)-specific monoclonal antibodies we determined that human Langerhans cells in situ express similar levels of ICOS-L, CD80, and CD86, compared to immature dendritic cells (DC) derived from monocytes in vitro. Maturation of DC strongly up-regulated CD80 and CD86 but did not significantly change ICOS-L levels. On coculture of "naive"CD4(+) T cells with mature DC in the presence of superantigen, ICOS was highly up-regulated on T cells, but played only a secondary role in the CD28-dominated release of TNF-alpha and IFN-gamma, and did not participate in the induction of IL-2. Cocultures of "effector" CD4(+) T cells with mature DC revealed CD28 as the drivin…

CD86EffectorImmunologyCD28chemical and pharmacologic phenomenahemic and immune systemsBiologyCell biologyICOS LIGANDInterleukin 10CTLA-4Immunology and AllergySecretionCD80European Journal of Immunology
researchProduct

Tumor-Derived Lactic Acid Modulates Dendritic Cell Activation and Differentiation.

2004

Abstract The tumor milieu can influence DC differentiation in vivo and in vitro. We analyzed DC differentiation in a 3-dimensional tumor model and propose a new mechanism of DC modulation by the tumor environment. Monocytes were cultured in the presence of IL-4 and GM-CSF within multicellular tumor spheroids (MCTS) generated from urothelial carcinoma (J82, UMUC3) and melanoma cell lines (MelIm, Mel108). Monocytes invaded the tumor spheroids and differentiated into tumor-associated dendritic cells (TADC) that displayed an altered phenotype compared to DC generated without tumor contact. The expression of CD1a was reduced on TADC whereas CD80, CD86 and CD16 were upregulated. In addition, TADC…

CD86MelanomaImmunologyAntigen presentationCellCell BiologyHematologyDendritic cellCD16Biologymedicine.diseaseBiochemistrymedicine.anatomical_structureBiochemistryCell cultureCancer researchmedicineCD80Blood
researchProduct

Differences in Dendritic Cell Activation and Distribution After Intravenous, Intraperitoneal, and Subcutaneous Injection of Lymphoma Cells in Mice

2007

Dendritic cells (DCs) are key antigen-presenting cells (APCs) for initiating immune responses. However, in recent years, several groups have shown the defective function of DCs in tumor-bearing mice and in cancer patients. Our aim was to study the effects of lymphoma on DC differentiation and maturation and to assess the input of the tumor microenvironment and intravasation of tumor cells on DC precursors. EL-4 lymphoma cells were administrated via different routes (intraperitoneal, subcutaneous, and intravenous) and DC phenotype was investigated. Bone marrow-derived DCs and APCs obtained from the spleen were examined by flow cytometry, and immunohistochemical analysis of lymphoma, lungs, l…

CD86Tumor microenvironmentCD40biologybusiness.industryhemic and immune systemschemical and pharmacologic phenomenaSpleenDendritic cellmedicine.diseasemedicine.anatomical_structureImmune systemImmunologybiology.proteinMedicinebusinessAnaplastic large-cell lymphomaCD80
researchProduct

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

1997

Escape from immune surveillance is critical for tumor progression in metastatic melanoma. We assessed the function of melanoma-derived dendritic cells (DCs) in patients presenting simultaneously with responding (rM) or progressing (pM) melanoma metastases. These rare coincidences allowed us to compare syngeneically the function of tumor DCs. CD83+ DCs were purified freshly from large responding (rDCs) or progressing (pDCs) metastases following chemo-immunotherapy. rDCs were 5 times more potent inducers of allogeneic T-cell proliferation than the pDCs that were used as control. Phenotypic analysis showed a marked depression of CD86 expression on pDCs. Culture supernatants from pM showed prod…

Cancer ResearchT-LymphocytesImmune toleranceImmune systemAntigens CDAntigens NeoplasmAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntigen-presenting cellMelanomaCD86Membrane Glycoproteinsbusiness.industryMelanomaInterferon-alphahemic and immune systemsDendritic cellDendritic Cellsmedicine.diseaseInterleukin-10Neoplasm ProteinsTolerance inductionOncologyTumor progressionImmunologyCytokinesInterleukin-2Tumor EscapeB7-2 AntigenCisplatinbusinessCell DivisionInternational journal of cancer
researchProduct

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells

2014

Cladribine is a purine nucleoside analog developed to treat lymphoid malignancies. Reported therapeutic benefits for the autoimmune disease multiple sclerosis indicate additional immunomodulatory effects beyond the well-characterized cytotoxic activity causing lymphopenia. Here, we demonstrate that cladribine reduces the secretion of inflammatory cytokines and chemokines by murine and human dendritic cells, the most potent antigen-presenting cells. This compound also modulates the expression of the activation markers CD86 and MHC II. Furthermore, cladribine affects the T cell priming capacity of dendritic cells, resulting in reduced induction of interferon-γ- and tumor necrosis factor-α-pro…

Cell SurvivalT-LymphocytesT cellImmunologyBiologyMicePhagocytosismedicineAnimalsHumansImmunologic FactorsImmunology and AllergyCytotoxic T cellAntigen-presenting cellCladribineCells CulturedCell ProliferationPharmacologyCD86ChemotaxisCell DifferentiationDextransDendritic CellsDendritic cellmedicine.diseaseMice Inbred C57BLLeukemiamedicine.anatomical_structureImmunologyLeukocytes MononuclearCancer researchCladribineCytokinesTumor necrosis factor alphaFluorescein-5-isothiocyanatemedicine.drugInternational Immunopharmacology
researchProduct